KTTA Stock Analysis: Buy, Sell, or Hold?
KTTA - Pasithea Therapeutics Corp. Common Stock
$0.57
0.03 (5.40%)
▲
5d:
+1.43%
30d:
-21.22%
90d:
-26.23%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When KTTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KTTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KTTA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KTTA is currently trading at $0.57, which is considered slightly low relative to its 30-day fair value range of $0.55 to $0.72.
Technical Outlook: Technically, KTTA is in a downtrend. Immediate support is located at $0.54, while resistance sits at $0.74. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: KTTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+456.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KTTA is in a downtrend. Immediate support is located at $0.54, while resistance sits at $0.74. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: KTTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+456.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.55 -
$0.72
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 456.7% below Wall St target ($3.00)
Trading Range Analysis
30-Day Trading Range
$0.55 -
$0.72
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.54
Resistance Level
$0.74
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.53
Wall Street Target
$3.00
(+456.7%)
Revenue Growth (YoY)
1498.1%
Share & Embed Analysis
Last updated: June 23, 2026 3:57 PM ET
Data refreshes hourly during market hours. Next update: 4:57 PM
Data refreshes hourly during market hours. Next update: 4:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KTTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
